$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

$plsh Overview Financials Valuation SEC Filings Company Website

2023 Form 10-K Financial Statement

#000149315224012107 Filed on April 01, 2024

Income Statement

Concept	2023	2022
Revenue	$2.385M	$1.627M
YoY Change	46.59%	-21.01%
Cost Of Revenue	$1.263M	$1.231M
YoY Change	2.64%	-81.01%
Gross Profit	$1.122M	$396.5K
YoY Change	182.99%	-108.97%
Gross Profit Margin	47.04%	24.37%
Selling, General & Admin	$1.456M	$1.093M
YoY Change	33.2%	-28.01%
% of Gross Profit	129.81%	275.77%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.713M	$1.670M
YoY Change	2.59%	-3.89%
% of Gross Profit	152.67%	421.14%
Operating Expenses	$6.668M	$6.049M
YoY Change	10.24%	298.29%
Operating Profit	-$5.546M	-$5.652M
YoY Change	-1.88%	-4.8%
Interest Expense	$1.556M	$2.048M
YoY Change	-24.04%	3145.91%
% of Operating Profit
Other Income/Expense, Net	-$2.469M	-$3.490M
YoY Change	-29.26%	-651.19%
Pretax Income	-$8.015M	-$9.143M
YoY Change	-12.33%	91.17%
Income Tax
% Of Pretax Income
Net Earnings	-$8.015M	-$9.143M
YoY Change	-12.33%	91.17%
Net Earnings / Revenue	-336.08%	-561.94%
Basic Earnings Per Share	-$0.48	-$0.62
Diluted Earnings Per Share	-$0.48	-$0.62
COMMON SHARES
Basic Shares Outstanding	16.63M shares	14.86M shares
Diluted Shares Outstanding	16.63M shares	14.86M shares

Balance Sheet

Concept	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.9K	$1.114M
YoY Change	-89.6%	-70.76%
Cash & Equivalents	$100.9K	$6.950K
Short-Term Investments	$14.93K	$1.107M
Other Short-Term Assets	$263.0K	$113.1K
YoY Change	132.54%	-59.36%
Inventory	$4.014M	$4.449M
Prepaid Expenses
Receivables	$264.0K	$206.1K
Other Receivables	$0.00	$500.0K
Total Short-Term Assets	$4.656M	$6.382M
YoY Change	-27.04%	-29.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.31M	$10.92M
YoY Change	-5.55%	-12.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$13.33M	$13.11M
YoY Change	1.68%	-10.75%
TOTAL ASSETS
Total Short-Term Assets	$4.656M	$6.382M
Total Long-Term Assets	$13.33M	$13.11M
Total Assets	$17.98M	$19.49M
YoY Change	-7.73%	-18.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.630M	$2.666M
YoY Change	73.65%	58.15%
Accrued Expenses	$2.914M	$2.090M
YoY Change	39.4%	28.7%
Deferred Revenue
YoY Change
Short-Term Debt	$11.90M	$10.32M
YoY Change	15.38%	52.6%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.45M	$15.07M
YoY Change	29.02%	49.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.827M	$6.560M
YoY Change	4.07%	-0.76%
Total Long-Term Liabilities	$6.827M	$6.560M
YoY Change	4.07%	-0.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.45M	$15.07M
Total Long-Term Liabilities	$6.827M	$6.560M
Total Liabilities	$26.27M	$21.63M
YoY Change	21.45%	29.69%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.291M	-$2.145M
YoY Change
Total Liabilities & Shareholders Equity	$17.98M	$19.49M
YoY Change	-7.73%	-18.06%

Cashflow Statement

Concept	2023	2022
OPERATING ACTIVITIES
Net Income	-$8.015M	-$9.143M
YoY Change	-12.33%	91.17%
Depreciation, Depletion And Amortization	$1.713M	$1.670M
YoY Change	2.59%	-3.89%
Cash From Operating Activities	-$1.524M	-$2.400M
YoY Change	-36.47%	-38.82%
INVESTING ACTIVITIES
Capital Expenditures	$65.32K	$243.8K
YoY Change	-73.21%	-249.62%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$46.83K
YoY Change	-100.0%	-93.17%
Cash From Investing Activities	-$65.32K	-$197.0K
YoY Change	-66.84%	-137.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.684M	$2.584M
YoY Change	-34.83%	-22.53%
NET CHANGE
Cash From Operating Activities	-$1.524M	-$2.400M
Cash From Investing Activities	-$65.32K	-$197.0K
Cash From Financing Activities	$1.684M	$2.584M
Net Change In Cash	$93.97K	-$12.82K
YoY Change	-832.83%	-80.15%
FREE CASH FLOW
Cash From Operating Activities	-$1.524M	-$2.400M
Capital Expenditures	$65.32K	$243.8K
Free Cash Flow	-$1.590M	-$2.643M
YoY Change	-39.86%	-29.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001552189
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2023	PLSH	Employer Retention Credit EmployerRetentionCredit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023	PLSH	Proceeds From Payroll Protection Sba Loans ProceedsFromPayrollProtectionSBALoans		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	PLSH	Goodwill Recorded In Acuisition GoodwillRecordedInAcuisition		usd
CY2022	PLSH	Preferred Shares Issued In Acquisition PreferredSharesIssuedInAcquisition		usd
CY2022	PLSH	Inventory Recorded In Acquisition InventoryRecordedInAcquisition		usd
CY2022	PLSH	Assets From Acquisition AssetsFromAcquisition		usd
CY2023	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash		usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2022Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2022Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
CY2023	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
CY2023Q4	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Vested And Exercisable In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionVestedAndExercisableInPeriodWeightedAverageIntrinsicValue		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38190
CY2023	dei	Entity Registrant Name EntityRegistrantName	Panacea Life Sciences Holdings, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1085858
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5910 S University Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	C18-193
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Greenwood Village
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80121
CY2023	dei	City Area Code CityAreaCode	800
CY2023	dei	Local Phone Number LocalPhoneNumber	985-0515
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	3529070	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17645352	shares
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100922	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6951	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	263970	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	206127	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4013525	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14933	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263003	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113098	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4656353	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6382263	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3864591	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6448068	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3014450	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2188810	usd
CY2023Q4	us-gaap	Assets Assets	17983462	usd
CY2022Q4	us-gaap	Assets Assets	19489449	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4629591	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2666076	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2913781	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2090271	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	115000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	346671	usd
CY2023Q4	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2022Q4	PLSH	Paycheck Protection Loan PaycheckProtectionLoan	99100	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19448031	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15073921	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3254021	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26274916	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21633993	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17645352	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17645352	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14965317	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14965317	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1765	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25628442	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33922898	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8291454	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17983462	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2384956	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1262979	usd
CY2023	us-gaap	Gross Profit GrossProfit	1121977	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5211719	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1456412	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6668131	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5546154	usd
CY2023	us-gaap	Interest Expense InterestExpense	1555877	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1092429	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22816	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	27598	usd
CY2022	PLSH	Employer Retention Credit EmployerRetentionCredit	253791	usd
CY2023	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	178411	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	748	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	681546	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2469147	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8015301	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8015301	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16627458	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16627458	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14862077	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14862077	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2144544	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23097	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	135000	usd
CY2023	PLSH	Stock Issued During Period Value Preferred Series E Shares Issued In Acquisition StockIssuedDuringPeriodValuePreferredSeriesESharesIssuedInAcquisition	1635295	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8015301	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8291454	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-8291454	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8015301	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9142584	usd
CY2023	us-gaap	Depreciation Depreciation	1712969	usd
CY2022	us-gaap	Depreciation Depreciation	1669690	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22816	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1092429	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2660105	usd
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-538583	usd
CY2023	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest	-74999	usd
CY2022	PLSH	Non Cash Settlement Of Convertible Note And Accrued Interest NonCashSettlementOfConvertibleNoteAndAccruedInterest	253791	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	61401	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	38329	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1067304	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-431317	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-38369	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-297391	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	184448	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	149905	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-165230	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1986613	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1083188	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	468113	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	458773	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1524463	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2399579	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	46832	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65322	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	243804	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65322	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196972	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	135000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1100000	usd
CY2022	PLSH	Proceeds From Payroll Protection Sba Loans ProceedsFromPayrollProtectionSBALoans	253791	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	272075	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	660511	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1797889	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4090448	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	292942	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1683756	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2583728	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93971	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12823	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6951	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19774	usd
CY2023	PLSH	Goodwill Recorded In Acuisition GoodwillRecordedInAcuisition	825640	usd
CY2023	PLSH	Preferred Shares Issued In Acquisition PreferredSharesIssuedInAcquisition	1646134	usd
CY2023	PLSH	Inventory Recorded In Acquisition InventoryRecordedInAcquisition	-400774	usd
CY2023	PLSH	Assets From Acquisition AssetsFromAcquisition	-419720	usd
CY2022	PLSH	Conversion Of Preferred Shares To Note Payable ConversionOfPreferredSharesToNotePayable	385000	usd
CY2022	PLSH	Issuance Of Common Stock For Services Non Cash IssuanceOfCommonStockForServicesNonCash	55000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	261899	usd
CY2023Q4	us-gaap	Area Of Land AreaOfLand	51000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33900000	usd
CY2023Q4	PLSH	Cash And Liquid Stock CashAndLiquidStock	100000	usd
CY2023Q4	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	80200	shares
CY2022Q4	us-gaap	Investment Owned Balance Shares InvestmentOwnedBalanceShares	1203000	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zdGNQNrmOghi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i><span id="xdx_868_zq39VW5fJ0qi">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The audited consolidated financial statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14933	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1107362	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1107362	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1092429	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14933	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3014450	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2188810	usd
CY2023Q4	PLSH	Customer Advances Payments CustomerAdvancesPayments	349705	usd
CY2022Q4	PLSH	Customer Advances Payments CustomerAdvancesPayments	368065	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	24585	usd
CY2023	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	156298	usd
CY2022	PLSH	Payments Received For Unearned Revenue PaymentsReceivedForUnearnedRevenue	412891	usd
CY2023	PLSH	Revenue Earned Amount RevenueEarnedAmount	174658	usd
CY2022	PLSH	Revenue Earned Amount RevenueEarnedAmount	69411	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	349705	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	368065	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4448725	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14368299	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8637660	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14368299	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8637660	shares
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1262674	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1694574	usd
CY2023Q4	PLSH	Packaging Supplies PackagingSupplies	29511	usd
CY2022Q4	PLSH	Packaging Supplies PackagingSupplies	20120	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4013525	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13683915	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13198873	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13683915	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13198873	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7235847	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5522878	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6448068	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7675995	usd
CY2023	us-gaap	Depreciation Depreciation	1712969	usd
CY2022	us-gaap	Depreciation Depreciation	1669690	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	850362	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	870530	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1870978	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1863501	usd
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2030-12-31
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3864591	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3242381	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3972696	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3347331	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3254021	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2987208	usd
CY2023Q4	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	718675	usd
CY2022Q4	PLSH	Shortterm Portion Of Operating Lease Liability ShorttermPortionOfOperatingLeaseLiability	360123	usd
CY2023Q4	PLSH	Unpaid Balance UnpaidBalance	2195106	usd
CY2022Q4	PLSH	Unpaid Balance UnpaidBalance	1730136	usd
CY2023Q4	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2913781	usd
CY2022Q4	PLSH	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	2090259	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y11M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	560626	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	458772	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	827996	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	830307	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	764830	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	474122	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1451002	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4348257	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	375561	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3972696	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3572864	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	650000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	385000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	346854	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.80
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	205000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.21
CY2023	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P4Y1M9D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	551854	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.841
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	551854	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.84
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	2500
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1117092	shares
CY2022Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	2.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	12851	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1104243	shares
CY2023Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare	1.79
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y1M6D
CY2023Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	1104243	shares
CY2023Q4	PLSH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice	1.79
CY2023	PLSH	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	107993	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1793483	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	33922898	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.219	pure
CY2023	PLSH	Effective Income Tax Rate Reconciliation Right Of Use Assets And Liabilities EffectiveIncomeTaxRateReconciliationRightOfUseAssetsAndLiabilities	-0.027	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036	pure
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8015000.000	usd

Files In Submission

Name	View Source	Status
0001493152-24-012107-index-headers.html	Edgar Link	pending
0001493152-24-012107-index.html	Edgar Link	pending
0001493152-24-012107.txt	Edgar Link	pending
0001493152-24-012107-xbrl.zip	Edgar Link	pending
ex10-10.htm	Edgar Link	pending
ex10-10_001.jpg	Edgar Link	pending
ex10-10_002.jpg	Edgar Link	pending
ex10-10_003.jpg	Edgar Link	pending
ex10-10_004.jpg	Edgar Link	pending
ex10-10_005.jpg	Edgar Link	pending
ex10-10_006.jpg	Edgar Link	pending
ex10-10_007.jpg	Edgar Link	pending
ex10-10_008.jpg	Edgar Link	pending
ex10-10_009.jpg	Edgar Link	pending
ex10-10_010.jpg	Edgar Link	pending
ex10-10_011.jpg	Edgar Link	pending
ex10-10_012.jpg	Edgar Link	pending
ex10-10_013.jpg	Edgar Link	pending
ex10-10_014.jpg	Edgar Link	pending
ex10-10_015.jpg	Edgar Link	pending
ex10-10_016.jpg	Edgar Link	pending
ex10-10_017.jpg	Edgar Link	pending
ex10-10_018.jpg	Edgar Link	pending
ex10-10_019.jpg	Edgar Link	pending
ex10-10_020.jpg	Edgar Link	pending
ex10-10_021.jpg	Edgar Link	pending
ex10-10_022.jpg	Edgar Link	pending
ex10-10_023.jpg	Edgar Link	pending
ex10-10_024.jpg	Edgar Link	pending
ex10-10_025.jpg	Edgar Link	pending
ex10-10_026.jpg	Edgar Link	pending
ex10-10_027.jpg	Edgar Link	pending
ex10-10_028.jpg	Edgar Link	pending
ex10-10_029.jpg	Edgar Link	pending
ex10-10_030.jpg	Edgar Link	pending
ex10-10_031.jpg	Edgar Link	pending
ex10-13.htm	Edgar Link	pending
ex10-13_001.jpg	Edgar Link	pending
ex10-13_002.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex3-10.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plsh-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
plsh-20231231_cal.xml	Edgar Link	unprocessable
plsh-20231231_def.xml	Edgar Link	unprocessable
plsh-20231231_lab.xml	Edgar Link	unprocessable
plsh-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh

2023 Form 10-K Financial Statement

#000149315224012107 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH Panacea Life Sciences Holdings Inc Stock $plsh

2023 Form 10-K Financial Statement

#000149315224012107 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLSH
Panacea Life Sciences Holdings Inc Stock $plsh